(Q34107488)

31 July 2017

1 reference

title

Update on the therapeutic potential of PDE4 inhibitors (English)

1 reference

31 July 2017

Hazel J Dyke

1

1 reference

PubMed ID

11772317

31 July 2017

John G Montana

series ordinal

2

1 reference

PubMed ID

11772317

31 July 2017

language of work or name

English

0 references

publication date

1 January 2002

1 reference

Expert Opinion on Investigational Drugs

31 July 2017

1 reference

31 July 2017

11

1 reference

31 July 2017

1-13

1 reference

31 July 2017

1

1 reference

Phosphorylation-Dephosphorylation of Enzymes

31 July 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.1.1

Diversity in cyclic nucleotide phosphodiesterase isoenzyme families

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.1.1

Cyclic nucleotide phosphodiesterases: relating structure and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.1.1

Phosphodiesterase isozymes: molecular targets for novel antiasthma agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.1.1

Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.1.1

The therapeutic potential of PDE4 inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.1.1

Phosphodiesterase 4 inhibitors, structurally unrelated to rolipram, as promising agents for the treatment of asthma and other pathologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.1.1

Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.1.1

New phosphodiesterase inhibitors as therapeutics for the treatment of chronic lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.1.1

Bioavailability of the oral selective phosphodiesterase 4 inhibitor cilomilast

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.1.1

Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.1.1

Dextran sulfate sodium-induced colonic histopathology, but not altered epithelial ion transport, is reduced by inhibition of phosphodiesterase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.1.1

Effects of the phosphodiesterase inhibitor rolipram on streptococcal cell wall-induced arthritis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.1.1

Cyclic-3',5'-nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.1.1

Suppression of experimental systemic lupus erythematosus (SLE) in mice via TNF inhibition by an anti-TNFalpha monoclonal antibody and by pentoxiphylline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.1.1

21 January 2018

Identifiers

DOI

10.1517/13543784.11.1.1

1 reference

31 July 2017

1 reference

PubMed ID

11772317